- Price
- $158.07
- Day
- +8.55%
- Mkt Cap
- $62.72B
- 52W Range
- $22.28 – $176.66
- Volume
- 19.12M
- Beta
- 0.90
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part
Moderna, Inc‘s (NASDAQ:MRNA) biggest problem is no longer proving that its mRNA technology can work against cancer. Investors got that answer in August.
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
Cancer vaccine momentum is doing the work for Moderna (NASDAQ:MRNA | MRNA Price Prediction) once again on Thursday, extending one of the sharpest one-month runs in large-cap biotech this year without a fresh disclosure attached to it.
Moderna Stock Is Surging: What's Going On?
Moderna Inc. (NASDAQ:MRNA) shares are popping Thursday, extending a month-long rally that began with a Phase 3 cancer vaccine breakthrough.
Breakfast News: Why Merck Should Buy Moderna
Forgent reports bumper quarter, Nvidia joins the AI safety debate, and more
Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?
Shares of Moderna MRNA have staged a remarkable comeback this year as investors increasingly warm to the possibility that the company can rebuild its business beyond COVID-19 vaccines. After becoming one of the biggest pandemic winners, Moderna struggled with sharply lower COVID-19 vaccine demand, declining revenues and mounting losses, sending its stock tumbling from its pandemic-era highs.